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Abstract 
Background: Melanoma is the most lethal type of skin cancer and its incidence is progressively increasing. The 
introductions of immunotherapy and targeted therapies have tremendously improved the treatment of melanoma. 
Selective inhibition of BRAF by vemurafenib results in objective clinical responses in around 50 % of patients suffering 
from BRAFV600 mutated melanoma. However, drug resistance often results in hampering long-term tumor control. 
Alternatively, immunotherapy by vaccination with natural dendritic cells (nDCs) demonstrated long-term tumor control 
in a proportion of patients. We postulate that the rapid tumor debulking by vemurafenib can synergize the long-term 
tumor control of nDC vaccination to result in an effective treatment modality in a large proportion of patients. Here, we 
investigated the feasibility of this combination by analyzing the effect of vemurafenib on the functionality of nDCs.
Methods: Plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) were isolated from PBMCs obtained from buffy coats 
from healthy volunteers or vemurafenib-treated melanoma patients. Maturation of pDCs, mDCs and immature mono-
cyte-derived DCs was induced by R848 in the presence or absence of vemurafenib and analyzed by FACS. Cytokine 
production and T cell proliferation induced by mature DCs were analyzed.
Results: Vemurafenib inhibited maturation and cytokine production of highly purified nDCs of healthy volunteers 
resulting in diminished allogeneic T cell proliferation. This deleterious effect of vemurafenib on nDC functionality was 
absent when total PBMCs were exposed to vemurafenib. In patients receiving vemurafenib, nDC functionality and T 
cell allostimulatory capacity were unaffected.
Conclusion: Although vemurafenib inhibited the functionality of purified nDC of healthy volunteers, this effect was 
not observed when nDCs were matured in the complete PBMC fraction. This might have been caused by increased 
vemurafenib uptake in absence of other cell types. In accordance, nDCs isolated from patients on active vemurafenib 
treatment showed no negative effects. In conclusion, our results pave the way for a combinatorial treatment strategy 
and, we propose that combining vemurafenib with nDC vaccination represent a powerful opportunity that deserves 
more investigation in the clinic.
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Background
Melanoma is a highly malignant melanocyte-derived 
tumor with a rising incidence. It is the most lethal of 
all skin cancers, accounting for 80  % of all skin cancer 
related deaths while representing only 4  % of all cases 
[1]. Recently, advances in both targeted therapies, as well 
as, immunotherapy have finally begun to show effective-
ness against metastatic melanoma [2–7]. Mutations in 
the BRAF signaling pathway have been identified as one 
of the drivers of melanoma. Mutations in the BRAF gene 
can be detected in 50–60 % of cutaneous melanomas and 
mutations in the NRAS gene in 10–20  % [8, 9]. These 
mutations lead to constitutive activation of the mitogen 
activated protein kinase (MAPK) pathway, which in turn, 
results in increased cell proliferation and survival [10, 
11]. Targeted agents directed against the MAPK pathway, 
mostly small molecule inhibitors, such as vemurafenib, 
have recently demonstrated clinical efficacy in metastatic 
disease [2, 3, 12]. Vemurafenib is a selective inhibitor of 
mutated BRAF and shows great efficacy in metastatic 
melanoma patients harboring the BRAFV600 mutation 
[2, 3, 12]. Objective clinical responses are seen in around 
50 % of all patients and the drug is generally well tolerated 
[2, 3, 12]. Despite the rapid responses and high response 
rates, drug resistance develops in the vast majority of 
patients, which clearly is an obstacle for achieving long-
term tumor control. Even more, it has been reported that 
tumors might become dependent on vemurafenib, which 
has led to the postulation of intermitted treatment sched-
ule in order to prevent resistance [13].
The other novel treatment modality for melanoma, 
which even was designated as breakthrough of the year 
2013 [14], is the use of immunotherapy. Broadly immuno-
therapy can be divided in cellular immunotherapy, such 
as dendritic cell (DC) vaccination, and antibody-based 
immunotherapy, such as immune check point blockade 
[15]. DCs are professional antigen presenting cells that 
can be loaded with melanoma-associated antigens and 
used to mount an immune response against tumor cells 
by activating cytotoxic T cells. DC vaccination for mela-
noma has been explored in many phase I and II studies. 
Thus far, virtually all of these clinical studies have been 
performed with ex vivo differentiated monocyte-derived 
DCs (moDCs) or from CD34+ progenitors. Although 
numerous vaccination studies demonstrated the immu-
nogenicity of tumor antigen-loaded DCs, the number of 
objective clinical responses has been limited, hampering 
its implementation as a novel form of standard treatment. 
However, DC vaccination still has untapped potential as, 
some stage IV melanoma patients did experience long 
lasting clinical responses. Additionally, in stage III mela-
noma there was a favorable overall survival benefit after 
adjuvant DC vaccination [16]. Additionally, recent trials 
exploiting naturally occurring DC subsets (nDCs), which 
circulate in the blood, as a vaccine vehicle showed prom-
ising increases in overall survival [17, 18].
Another immunotherapeutic strategy, the blocking of 
CTLA-4 with ipilimumab led to enhanced T cell activa-
tion and increased tumor rejection [4, 19] and resulted 
in long-term tumor control in about 20  % of patients. 
As number of studies showed that BRAF inhibition 
increased the number of intratumoral cytotoxic T cells 
and increased expression of tumor-associated anti-
gens on tumor cells [20–23], it was hypothesized that 
BRAF inhibition could synergize with CTLA-4 block-
ade. Unfortunately, the first trial to study combination 
of ipilimumab and vemurafenib was terminated pre-
maturely due to severe hepatotoxicity [24]. This study 
showed that the combination of vemurafenib with 
checkpoint inhibition is not feasible, at least not when 
given simultaneously. Recently, other studies inves-
tigated the potential of combinations of more BRAF 
inhibitors, like dabrafenib, and checkpoint inhibition 
(ipilimumab) with or without additional treatment 
with the MEK inhibitor trametinib (NCT01940809 and 
NCT02130466). Preliminary results indicate that these 
combinations are tolerated, and do not result in severe 
hepatotoxicity. Nevertheless, the combination of three 
agents was discontinued based on the development of 
colitis followed by intestinal perforation [25–27]. We 
have recently shown that using natural blood-borne 
DC subsets as vehicles for DC vaccination, markedly 
improved responses in terms of overall survival could 
be observed, with minimal toxicity [17, 28]. With that in 
mind, we postulate that DC vaccination might be a can-
didate to be combined with vemurafenib. In this preclin-
ical study, we investigated the feasibility of combining 
DC vaccination with vemurafenib by studying whether 
modulation of MAPK signaling pathway affected func-
tion and maturation of nDCs in healthy volunteers or 
melanoma patients receiving vemurafenib.
Methods
Cells
Isolation of nDCs was described previously [29]. Briefly, 
buffy coats were obtained from healthy volunteers 
with informed consent according to institutional and 
international guidelines. Blood from end-stage meta-
static melanoma patients was collected prior to start 
of vemurafenib treatment and after 1  month vemu-
rafenib therapy. This study was approved by the local 
Institutional Review Board (Committee on Research 
involving Human Subjects Arnhem-Nijmegen) and in 
accordance with the declaration of Helsinki. Written 
informed consent was obtained from all patients. After 
peripheral blood mononuclear cells (PBMC) isolation, 
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plasmacytoid DCs (pDCs) were purified by positive 
isolation using anti-BDCA-4-conjugated magnetic 
microbeads, and BDCA-1+ myeloid DCs (mDCs) were 
purified using anti-CD1c-conjugated microbeads (both 
Miltenyi Biotec, Bergisch-Gladbach, Germany) after 
B cell depletion. Plasmacytoid DC and mDC purity 
was routinely up to 95 %, as assessed by double stain-
ing with BDCA-2/CD123 or CD11c/CD1c (all Miltenyi 
Biotec). DCs were cultured in X-VIVO-15 (Lonza, Ver-
viers, Belgium) supplemented with 10 % human serum 
(Sanquin, Nijmegen, the Netherlands). DC maturation 
was induced through addition of 4  μg/ml R848 (Axx-
ora, San Diego, CA). Monocyte-derived DCs (moDCs) 
were generated from adherent PBMCs, by culturing in 
the presence of IL-4 (500 U/ml) and GM-CSF (800 U/
ml) (both Cellgenix, Freiburg, Germany). Cells were 
cultured in X-VIVO 15 medium supplemented with 
2 % human serum and harvested on day 6 as immature 
DC. Immature DC or mDCs were activated through 
the addition of 4 μg/ml R848 and/or 20 μg/ml Poly I:C 
(Sigma-Aldrich).
Flow cytometry
Purity of pDCs and mDCs after isolation and the phe-
notype of the pDC populations were determined by flow 
cytometry. The following primary monoclonal antibodies 
(mAbs) and the appropriate isotype controls were used: 
anti-BDCA1-FITC, BDCA2-PE, BDCA4-PE and CD123-
APC (all Miltenyi Biotec); mIgG1-PE, mIgG1-APC, anti-
CD11c-FITC or -APC, anti-HLA-ABC-PE (W6/32), 
anti-CD80-PE, or -APC, or -PeCy7, anti-CD86-PE, or 
-APC (all BD Bioscience Pharmingen, San Diego, CA, 
USA) anti-PD-L1-APC, anti-PD-L2-PE; anti-CD40-PE, 
anti-CD83-PE (Beckman Coulter, Mijdrecht, the Nether-
lands); anti-MHC-II-APC (eBioscience).
The phenotype of the DC populations after treat-
ment with vemurafenib, dabrafenib, trametinib or a 
combination was determined by staining with the fol-
lowing antibodies and appropriate isotype controls: 
anti-CD80-PE-Cy7, anti-CD86 APC, anti-PD-L1-PE, 
anti-HLA-ABC-V450, anti HLA-DR-BV510, mIgG1-PE-
Cy7, mIgG1-PE (all BD biosciences) and mIgG1-APC 
(eBioscience).
Reagents
Vemurafenib (PLX4032 or RG7204) was kindly donated 
by Roche for study purpose. Vemurafenib was dissolved 
in DMSO to a stock concentration of 1  mg/ml. The 
vemurafenib stock was freshly diluted before each experi-
ment to 60  μg/ml unless stated otherwise. Dabrafenib 
and trametinib were obtained from Alsachim (Illkirch-
Graffenstaden, France). Both drugs were diluted freshly 
to 90 and 12 ng/ml, respectively.
Antigen‑specific T cell activation
pDCs and mDCs from a HLA-A2.1 + donor were loaded 
with different concentrations of a melanoma-specific 
peptide (gp100280:288) or irrelevant peptide (tyrosi-
nase369:376) in 96-well round bottom plates (10  ×  103 
cells per well). After approximately 2  h, R848, two con-
centrations of vemurafenib and gp100280:288-specific T 
cells (50 × 103 cells per well) were added. After overnight 
incubation, CD69 and CD25 expression on the CD3+ 
gp100280:288-specific T cells was measured by flow cytom-
etry using PE-Cy5 conjugated mouse anti-human CD69, 
APC-conjugated CD25 and BV421-conjugated CD3 (all 
BD biosciences).
Mixed lymphocyte reaction
Allogeneic peripheral blood lymphocytes (PBLs) were 
co-cultured with differently matured pDCs, mDCs and 
moDCs in a 96-well round-bottom plate (pDC/PBL ratio 
1:20 with 105 PBLs). After 3  days of culture at 37  °C, 
1 μCi/well ([0.037 MBq]/well; MP Biomedicals, Amster-
dam, the Netherlands) of [3H]-thymidine was added for 
12 h and incorporation was measured in a beta-counter.
Cytokine detection
pDCs and mDCs were cultured overnight at a concentra-
tion of 105 DCs/100  μl/well in a 96-well round-bottom 
(pDCs) or flat-bottom (mDC) plate. Supernatants were 
collected from DC cultures after 16 h of activation; IL-6, 
TNFα, RANTES, IP-10 and MIP-1α production was 
measured using a human Multiplex kit (BMS817FF from 
eBioscience) according to manufacturer’s instructions. 
IFNα production was measured by ELISA according to 
manufacturer’s instructions.
Statistics
All experiments were performed at least three times and 
results are shown as the mean  ±  SEM. Data sets were 
either tested by a Student’s t test or by one-way ANOVA 
followed by Newman–Keuls or Dunnett’s multiple com-
parison test.
Results
At steady‑state blood concentration vemurafenib inhibits 
nDC maturation and cytokine secretion in vitro
We explored whether vemurafenib had any effect on 
the viability, phenotype or maturation of the nDC sub-
sets, pDCs and mDCs. Both DC subsets were exposed 
to 60  μg/ml of vemurafenib, which is higher than in 
most other studies and higher than the IC50 for most 
tumor cells in vitro [30]. However, 60 μg/ml is the aver-
age steady-state concentration (Ctrough; 34–93  μg/ml) of 
vemurafenib in the blood of patients treated with vemu-
rafenib determined in pharmacokinetic studies [3, 31]. 
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As such, this is the concentration of vemurafenib that 
circulating nDCs will be exposed to. This concentration 
of vemurafenib had deleterious effects on nDC viability 
cultured in medium containing 2 % human serum (Fig. 1; 
Additional file 1: Fig. S1). Taking into account that >99 % 
of vemurafenib in the blood is protein bound and the 
low amount of serum (and protein) used here, we inves-
tigated the effect of increasing the amount of serum to 
5–10 %. DC viability was improved with both concentra-
tions and 10  % serum restored pDC and mDC viability 
to the level of untreated cells (Fig. 1). In accordance with 
previous findings, vemurafenib had no negative effects 
on T cell and B cell viability (Additional file  2: Fig.  S2) 
[20]. Additionally, there was no effect on the viability of 
pDCs and mDCs matured in the presence of vemurafenib 
at a concentration of 10  % human serum (Fig.  1). The 
next step was to investigate whether exposure to vemu-
rafenib during maturation at a concentration of 10  % 
human serum had any effect on the resulting phenotype. 
The single stranded RNA analog R848 (agonist for TLR-
7/8) was used to trigger DC maturation as it stimulates 
both mDCs and pDCs. R848 induces CD40, CD80 and 
CD86 indicative for maturation of both pDCs and mDCs 
(Fig.  2a, b). However, exposure to vemurafenib clearly 
hampered the maturation of these blood DC subsets as 
all markers failed to reach similar expression levels as 
cells cultured without vemurafenib.
Next, we determined whether vemurafenib could also 
modulate TLR-induced proinflammatory cytokine and 
chemokine secretion by pDCs and mDCs. We observed 
a marked decrease in the secretion of IL-6, TNF-a, and 
IP-10 by R848 stimulated pDCs and mDCs (Fig.  2c, 
d). Additionally, vemurafenib exposure also inhibited 
interferon-α (IFN-α) production by pDCs.
In order to investigate whether these observed effects 
were exclusively vemurafenib-related or class-specific 
for BRAF inhibition, we performed similar experiments 
with the BRAF inhibitor dabrafenib. Furthermore, we 
extended our analysis by studying the effects of the MEK 
inhibitor trametinib and the different combinations of 
these inhibitors. Importantly, the IC50 values for both 
dabrafenib and trametinib are approximately 40 times 
lower compared to vemurafenib under cell-free assay 
conditions. In  vivo, this translates into much lower lev-
els compared to vemurafenib, the Cthrough values for dab-
rafenib and trametinib are 90 and 12 ng/ml, respectively 
[32, 33], compared to 60 µg/ml for vemurafenib. We cul-
tured mDCs and pDCs with the drugs either alone or 
in various combinations in the presence of R848. After 
overnight activation we observed that while vemurafenib 
inhibited the R848 induced-maturation of both pDCs 
and mDCs, neither dabrafenib nor trametinib had a sig-
nificant impact on the upregulation of CD80, CD86, 
PD-L1, MHC-I or MHC-II (Fig.  3a, b). Similarly, the 
combination of vemurafenib and trametinib inhibited 
maturation just like vemurafenib while the combination 
of dabrafenib and trametinib did not (Fig.  3a, b). Taken 
together, vemurafenib exerts negative off-target effects 
on both mDCs and pDCs obtained from healthy donors, 
while other small molecule inhibitors with higher speci-
ficity and selectivity do not hinder mDC or pDC matura-
tion in vitro.
Exposure to vemurafenib leads to downregulation 
of MHC molecules, decreased allostimulatory capacity, 
and minimally decreased antigen‑specific T cell activation
The expression levels of MHC class I, and MHC class II, 
which are necessary to activate CD8+ cytotoxic T cells, 
and CD4+ helper T cells, respectively was also meas-
ured. Although cytotoxic T cells are the most important 
mediators of anti-tumor immune responses, induction of 
CD4 T cells improves clinical outcome, probably by stim-
ulating B cell function [34, 35]. In addition to decreased 
maturation of pDCs and mDCs, maturation-induced 
upregulation of MHC class I and MHC class II was also 
diminished after exposure to vemurafenib, indicating a 
Fig. 1 Vemurafenib bioavailability determines survival of pDCs and mDCs. Freshly isolated plasmacytoid DCs and myeloid DCs were cultured in 
increasing concentrations of vemurafenib and human serum and cell viability was determined after 24 h by FACS analysis
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possible decreased capacity of antigen presentation to T 
cells (Fig.  4a, b). Concomitantly, there was a significant 
decrease in allogeneic T cell proliferation induced by 
pDCs and mDCs matured in the presence of vemurafenib 
(Fig. 4c, d). The observed decrease in proliferation could 
not be due to increased expression of co-inhibitory mole-
cules after DC stimulation in the presence of vemurafenib 
because PD-L2 was not expressed by either subset (data 
not shown) and PD-L1 upregulation was completely 
absent (Fig.  2a, b). Thus although vemurafenib inhibits 
the upregulation of PD-L1 the proliferation of allogeneic 
T cells is not enhanced but decreased, most likely due to 
the reduced expression of MHC molecules after stimula-
tion of DC in the presence of vemurafenib. Furthermore, 
we examined whether vemurafenib affects the ability of 
pDCs and mDCs to prime antigen-specific T cells. For 
this we made use of Jurkat T cells that are transfected 
with the T cell receptor for gp100280:288. We observed 
that both pDCs and mDCs activated with R848 in the 
presence or absence of vemurafenib and loaded with var-
ious concentrations of the gp100280:288 peptide were able 
to significantly induce the activation of Jurkat T cells as 
evidenced by the specific upregulation of the IL-2 recep-
tor CD25 (Additional file 3: Fig. S3) and the early activa-
tion marker CD69 (Fig.  4e, f ). Although all conditions 
led to a significant activation compared to cells loaded 
with the irrelevant tyrosinase peptide, we observed that 
vemurafenib negatively affected the antigen-specific T 
Fig. 2 Vemurafenib impairs maturation of ex vivo cultured pDCs and mDCs. Freshly isolated pDCs (a) and mDCs (b) were cultured ex vivo and acti-
vated with R848 in presence or absence of 60 μg/ml vemurafenib. Graphs show the cell surface expression levels of CD80, CD86, CD40, and PD-L1 
after 18 h. Freshly isolated pDCs (c) and mDCs (d) were cultured ex vivo and activated with R848 in presence or absence of 60 μg/ml vemurafenib. 
Graphs show the levels of the cytokines IL-10, IL-6, TNFα and IFNα (only pDCs) measured in the supernatant after 18 h. Shown is the mean (+SEM) of 
six independent experiments *P < 0.05, **P < 0.01,***P < 0.001
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cell receptor signaling as the level of CD69 induction 
was lower under this condition. Though a clear inhibi-
tory effect on non-antigen specific T cell proliferation 
was observed, only a minute effect of vemurafenib on 
antigen-specific T cell activation could be detected. This 
discrepancy might be caused by prolonged (3 days) cul-
ture of T cells in the presence of vemurafenib, whereas in 
the antigen-specific T cell priming the readout was after 
18 h. These findings reflect the potential in vitro toxicity 
of vemurafenib on immune cells. Taken together, these 
data imply that vemurafenib minimally decreased the 
antigen-specific immunostimulatory ability of blood DC 
subsets.
The presence of immune cells mitigates the inhibitory 
effects of vemurafenib on DC maturation and cytokine 
secretion
Previous experiments studied the effects of vemu-
rafenib on isolated, purified nDC cultures. We wondered 
whether the presence of other immune cells during the 
Fig. 3 Dabrafenib and trametinib do not impair maturation of ex vivo cultured pDCs and mDCs. Freshly isolated pDCs (a) and mDCs (b) were cul-
tured ex vivo and activated with R848 in presence or absence of 60 μg/ml vemurafenib, 90 ng/ml dabrafenib and 12 ng/ml trametinib. Graphs show 
the cell surface expression levels of CD80, CD86, PD-L1, MHC-I and MHC-II after 18 h. Shown is the mean (+SEM) of three independent experiments 
*P < 0.05, **P < 0.01,***P < 0.001
Fig. 4 Vemurafenib impairs antigen presentation and allostimulatory capacity of ex vivo cultured pDCs and mDCs. Freshly isolated pDCs (a) and 
mDCs (b) were cultured ex vivo and activated with R848 in presence or absence of 60 μg/ml vemurafenib. Graphs show the cell surface expression 
levels of MHC class I and MHC class II after 18 h. Mixed lymphocyte reaction using freshly isolated, pDCs (c) and mDCs (d) stimulated with R848 
in presence or absence of 60 μg/ml vemurafenib. After maturation DCs were incubated with allogeneic PBLs and T cell proliferation was meas-
ured after 4 days with [3H] thymidine incorporation. d pDCs and mDCs from a HLA-A2.1 + donor were loaded with different concentrations of a 
melanoma-specific peptide (gp100280:288) or irrelevant peptide (tyrosinase369:376) in the presence of R848 with/without vemurafenib and gp100280:288 
specific T cells. Graphs show the cell surface expression levels of the early activation marker CD69 after overnight co-culture. Shown is the mean 
(+SEM) of at least three independent experiments *P < 0.05, **P < 0.01, ***P < 0.001
Page 7 of 11Tel et al. J Transl Med  (2016) 14:88 
exposure to vemurafenib, as would be the case in the 
blood stream, would have an effect on the outcome. To 
test this, we stimulated whole PBMC fractions of healthy 
volunteers with R848 in the presence or absence of 
vemurafenib. After 24 h the PBMCs were harvested and 
stained for DC-specific markers and maturation markers. 
These strategies allowed us to gate the DCs and quantify 
the expression of maturation markers (Fig.  5). In con-
trast to the purified nDC cultures the inhibitory effect 
of vemurafenib on pDC maturation is less pronounced. 
There was a significant decrease in CD80 expression 
but there was no effect on CD86 expression (Fig.  5a). 
The maturation of mDCs on the other hand was hardly 
hampered by vemurafenib (Fig. 5b). PD-L1 upregulation 
is still inhibited by vemurafenib, showing that the com-
pound is still active and reaching the cells. Furthermore, 
analysis of secreted cytokines in response to R848 with or 
without vemurafenib demonstrated no significant effects 
(Fig.  5c). Thus, vemurafenib has little to no deleterious 
effects in total PBMC cultures.
Vemurafenib does not inhibit ex vivo maturation of pDCs 
and mDCs isolated from melanoma patients on active 
treatment
We isolated PBMCs from three melanoma patients 
before and after 1  month receiving vemurafenib 
960 mg BID. We did not observe any significant change 
in the frequency of either pDCs or mDC after one 
month of vemurafenib treatment (Fig. 6a). We investi-
gated the effect of vemurafenib on pDC and mDC mat-
uration by stimulating freshly isolated PBMCs from 
patients on vemurafenib treatment in vitro with R848. 
These pDCs and mDCs matured normally, indicated 
by the significant increase in CD80, CD86, PD-L1 and 
Fig. 5 The presence of immune cells mitigates the inhibitory effects of vemurafenib on DC maturation and cytokine secretion. Freshly isolated 
PBMCs were cultured ex vivo and activated with R848 in presence or absence of 60 μg/ml vemurafenib. Graphs show the cell surface expression 
levels of CD80, CD86, CD40, and PD-L1 on pDCs (a) and mDCs (b) after 18 h. c Graphs show the levels of the cytokines IL-10, IL-6, TNFα, IL-1β, and 
IL-5 measured in the supernatant after 18 h. Shown is the mean (+SEM) of four independent experiments *P < 0.05, **P < 0.01, ***P < 0.001
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MHC-I (only for pDCs) (Fig. 6b). Additionally, the lev-
els of DC maturation before start of vemurafenib and 
after one month on vemurafenib were similar (Addi-
tional file  4: Fig.  S4). Next we investigated the effect 
of vemurafenib treatment on T cell activation. We 
isolated PBMCs from seven Patients receiving vemu-
rafenib and induced non-specific T cell proliferation 
by addition of PHA, which led to significant T cell 
proliferation in all cases (Fig.  6c). From a subset of 
these patients we also compared T cell proliferation 
before and 1 month after start of vemurafenib and saw 
no differences (Additional file  4: Fig.  S4) From these 
data, we can conclude that vemurafenib does not nega-
tively affect the frequency of nDC subsets in the blood, 
nor affects their maturation and also has no negative 
effects on T cell function.
Discussion
Approximately 50  % of melanoma tumors have an acti-
vating mutation in BRAF V600 [8, 9]. This has led to the 
development of specific BRAF inhibitors such as vemu-
rafenib and dabrafenib. Despite the rapid and impressive 
response rates, treatment with vemurafenib is limited 
due to the short duration of the response caused by rapid 
onset of resistance [2, 12, 36]. Other therapeutic oppor-
tunities in order to improve the efficacy of vemurafenib 
might be found in the combination with DC vaccina-
tion. Currently, DC vaccination faces the opposite set 
of challenges compared to vemurafenib. Many patients 
do not respond to initial treatment, possibly due to the 
enormous challenge of fighting a high tumor load in late 
stage patients. However, the patients that do respond have 
long-lasting tumor control with life expectancy measured 
Fig. 6 Vemurafenib does not inhibit ex vivo maturation of pDCs and mDCs isolated from melanoma patients on active treatment. PBMCs were iso-
lated from patients before and after 1 month on vemurafenib treatment. a The frequency of pDCs and mDCs in the PBMCs was measured by FACS 
analysis. b Freshly isolated PBMCs from melanoma patients after 1 month on vemurafenib treatment were cultured ex vivo and activated with R848. 
Graphs show the cell surface expression levels of CD80, CD86, PD-L1, MHC-I, and MHC-II on pDCs and mDCs after 18 h. c Freshly isolated PBMCs 
from melanoma patients after 1 month on vemurafenib treatment were stimulated with PHA and T cell proliferation was measured after 4 days with 
[3H] thymidine incorporation. Shown is the mean (+SEM) of seven independent experiments *P < 0.05, **P < 0.01, ***P < 0.001
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in years instead of months [17, 34, 37, 38]. This provides 
the tantalizing possibility of combining vemurafenib with 
DC vaccination. Vemurafenib treatment could lead to a 
rapid decrease in tumor load, giving the immune system 
enough time to mount an effective anti-tumor response 
that can eliminate residual tumor cells and vemurafenib 
resistant tumor cells.
Here, we performed an exploratory preclinical, ex vivo, 
study on the feasibility of combining vemurafenib treat-
ment with DC vaccination; specifically, we studied the 
potential off-target effects of vemurafenib on human 
natural blood DC subsets, which appear to be the supe-
rior vehicles for DC vaccination [17, 28, 39]. We found 
that the availability of vemurafenib is a crucial compo-
nent in testing its toxicity. In this study, we used the con-
centration of vemurafenib, which is found at steady state 
pharmacokinetics in patients undergoing treatment [31, 
40]. This is in contrast to other studies that have looked 
at the toxicity of vemurafenib on immune cells, includ-
ing lymphocytes and monocyte-derived DCs using very 
low concentrations of vemurafenib (0.5–5  µg/ml) [20, 
41]. We reasoned that our chosen concentration was 
the amount of vemurafenib that these blood-borne DCs 
would be exposed to. Initial experiments showed that 
this concentration of 60  µg/ml was toxic for pDCs and 
mDCs. Increased levels of human serum relieved this 
toxicity, which could be attributed to the fact that the 
majority of vemurafenib in the blood stream (>99  %) is 
protein bound, thus reducing the concentration of free 
vemurafenib [42]. These results already illustrate that it is 
very difficult to recreate the correct physiological contex-
ture when doing in vitro experiments and that one should 
always exercise caution when drawing conclusions. So 
at this concentration vemurafenib had no effect on nDC 
viability, but we did observe a clear and significant inhibi-
tion of DC maturation and cytokine secretion. However, 
when replicating this experiment using the whole PBMC 
fraction instead of the purified nDC subsets, we observed 
that vemurafenib had no effect on DC maturation, or 
cytokine secretion by the PBMCs. This could again be 
attributed to vemurafenib availability and thus the limited 
uptake of vemurafenib by the pDCs and mDCs. Finally, 
we studied pDCs and mDCs in PBMC fraction obtained 
from patients before and after 1  month of vemurafenib 
treatment. Likewise, DCs were not hampered in their 
ability to mature. Taken together our results clearly show 
no sign of negative effects of vemurafenib on DC sub-
sets of patients undergoing treatment. DC frequencies 
remain the same during treatment and also their function 
and maturation is unaffected. In all, the combination of 
vemurafenib with DC vaccination seems feasible.
One major concern with combination regimens is 
the increased risk of toxicity. Indeed the combination of 
vemurafenib with ipilimumab was unsuccessful because of 
increased hepatotoxicity. Currently, a phase II study eval-
uating the safety and benefit of sequential treatment with 
vemurafenib and ipilimumab is ongoing (NCT01673854) 
which is an approach to potentially decrease toxicity while 
gaining activity. The PD-1 receptor is another inhibitory 
receptor on T-cells that functions as an immune check-
point [43, 44]. Monoclonal antibodies that block PD-1, 
or its ligand PD-L1 (which is expressed on tumor cells) 
have demonstrated excellent clinical activity in patients 
with metastatic melanoma, while generally being less 
toxic than ipilimumab [5–7, 45]. One multi-modality 
approach would be the combination of vemurafenib with 
PD-1 or PD-L1 blockade. The combination vemurafenib 
and PD-L1 blockade is currently under investigation 
(NCT01656642). In light of our results, we would propose 
the combination of vemurafenib with DC vaccination. An 
increase in toxicity due to this combination treatment is 
not foreseen, as the toxicity level of DC vaccination on its 
own, is low consisting mostly of flu-like symptoms (Grade 
1–2 toxicity) [16, 17, 46, 47]. Other interesting targeted 
therapies are dabrafenib, trametinib, or the combination 
of dabrafenib and trametinib and combining those with 
DC vaccination. Indeed the combination of dabrafenib 
and trametinib seems to be more effective while not hav-
ing a higher toxicity profile than vemurafenib monother-
apy [27], though for the moment vemurafenib is still first 
line therapeutic option.
Lastly, in biopsies of melanoma metastases, an 
increased T cell infiltration after vemurafenib treatment 
was seen. Furthermore, a correlation between CD8 infil-
tration and clinical response was observed [22]. This 
again indicates no negative effects of vemurafenib on 
tumor-specific immune responses. Indeed the increased 
expression of tumor associated antigens by tumor cells 
after exposure to vemurafenib might even synergize with 
the activation of tumor-specific T cells by the DC vaccine 
[23], making this combination all the more attractive.
Conclusion
Our data shows that vemurafenib does not inhibit the 
functionality of naturally circulating DC subsets in the 
context of a complete immune system. Additionally, we 
show that pDCs and mDCs isolated from metastatic 
melanoma patients treated with vemurafenib display 
normal functionality. Given the extremely mild toxicity 
profile of DC vaccination, our results pave the way for a 
combinatorial treatment strategy consisting of combin-
ing vemurafenib with pDC and/or mDC vaccination. This 
protocol would combine the best of both worlds, rapid 
and efficient tumor debulking by vemurafenib with long 
lasting anti-tumor immune responses induced by DC 
vaccination.
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